H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...
Oyster Point Pharma (NASDAQ:OYST) priced an initial public offering of five million common shares at a price of $16 each to raise gross proceeds of $80-million. The offering is expected to close on Nov. 4. The company...